Alerta

BIS-ESTER AND AMIDE CATIONIC LIPIDS

Resumen de: WO2026006524A2

The present invention provides, in part, cationic lipid compounds of Formulae (I), (II), (III), (IV), (V), or (VI) or a pharmaceutically acceptable salt thereof. The compounds provided herein can be useful for delivery and expression of mRNA and encoded protein, e.g., as a component of liposomal delivery vehicle, and accordingly can be useful for treating various diseases, disorders and conditions, such as those associated with deficiency of one or more proteins.

NANOENCAPSULATION OF OLIVE PHENOLIC COMPOUNDS IN PROTEIN MATRICES

Resumen de: WO2026003770A1

A formulation for nutraceutical and/or pharmaceutical use based on protein nanoparticles is described, including a bioactive compound chosen from hydroxytyrosol, tyrosol, olive phenolic compounds, and mixtures thereof, and a zein protein matrix stabilized with sodium deoxycholate.

PIPERAZINE BASED DIVALENT IONIZABLE LIPIDS AND THEIR USES

Resumen de: WO2026005944A1

A compound having the structure (I) is provided. The compound is useful as a therapeutic agent in the form of a lipoplex, or in a form of a polyplex, in a form of a lipid nanoparticle, or in a form of a liposome, or in a form of a micelle, or in a form of an emulsion including a drug, vaccine, oligonucleotide, antibody, enzyme, protein, small molecule, or nucleotide.

LYOPHILIZED AND FROZEN MRNA-LNP FORMULATIONS

Resumen de: WO2026006617A1

The present invention relates to lyophilized and frozen pharmaceutical formulations comprising a nucleic acid (NA)-lipid nanoparticle (LNP) particle, wherein the NA-LNP particle comprises a nucleic acid encapsulated in the lipid nanoparticle, wherein the formulation further comprises an excipient comprising a lyoprotectant or cryoprotectant and a buffer, and wherein the lyoprotectant or cryoprotectant is a polyvinylpyrrolidone (PVP) or a polyethylene glycol (PEG). Methods of making the lyophilized and frozen formulations are also provided.

COMPOSITION FOR TARGETED DELIVERY OF THERAPEUTIC COMPOUNDS TO BONE TISSUE

Resumen de: WO2026002313A1

A system and method are disclosed for the production of drug delivery vesicles formed from hydroxyapatite (Ca10(PO4)6(OH)2), called apasomes, using a microfluidic device. The device comprises a first inlet with a bifurcated tube and a second inlet with an inlet tube. Hydroxyapatite nanoparticles and, optionally, therapeutic agents suspended in a second fluid are introduced into the device via the second inlet, while a miscible first fluid is introduced via the first inlet. The two fluids are combined at a mixing point within the device and the combination fluid travels through an elongate tube before exiting the device. Shear forces cause self-assembly of vesicles, the size of which can be modified by adjusting the flow rates, the shapes and dimensions of the tube, and the composition of the fluids. The method may also include refluxing, filtration and drying steps to enable scalable production of customizable drug delivery vesicles for therapeutic applications.

IONIZABLE LIPIDS AND LIPID NANOPARTICLES CONTAINING THEM FOR EXTRAHEPATIC DELIVERY

Resumen de: WO2026003403A1

It is provided a novel lipid of formula (I) or a pharmaceutically acceptable salt thereof, or a stereoisomer of any one of them, and a nanoparticle comprising the ionizable lipid, particularly as encapsulating agent, optionally comprising a molecule or a pharmaceutically active inside. It is also provided a lipid nanoparticle or a pharmaceutical composition comprising thereof for use in medicine, and the use of the lipid nanoparticles as encapsulating agents. Formula (I)

PHENOLIC ACID LIPID BASED CATIONIC LIPIDS

Resumen de: WO2026003373A1

The present invention provides lipids of Formula (I) to (IX) or subformulae thereof, or pharmaceutically acceptable salts thereof. Said lipids can be useful for the delivery and expression of mRNA and encoded protein, e.g. as a component of liposomal delivery vehicles, and accordingly can be useful for treating various diseases, disorders, and conditions, such as those associated with deficiency of one or more proteins. Compositions comprising lipid compounds of Formulae (I) to (X) and subformulae thereof, and mRNA encoding a peptide or protein may be administered to subjects in need thereof intranasally.

USE OF BLOCK COPOLYMERS COMPRISING A POLY(ETHYLENE OXIDE) WITH A C1 TO C3-ALKYLOXYMETHYL SIDE CHAINS BLOCK AND HYDROPHOBIC BLOCKS IN PARTICLES AND IN MEDICAL DEVICES

Resumen de: WO2026002534A1

The present invention refers to the use of novel polyoxyalkylene based block copolymers in particles or in medical devices, wherein the particles comprise at least one novel polyoxyalkylene based block copolymer and preferably at least one active agent.

LIPIDS AND LIPID NANOPARTICLES

Resumen de: WO2026003582A2

The disclosure provides for lipids that may be formulated in a delivery vehicle to facilitate the encapsulation of a wide range of single or multiple payloads including therapeutic, theragnostic, preventive, prophylactic, pre-emptive, and diagnostic agents, such as, without limitation, nucleic acids (e.g., RNA or DNA), proteins, peptides, and small molecule active pharmaceutical ingredients (APIs). Methods of delivering and/or producing a polypeptide of interest in a cell are also provided.

ALTERED MODIFIED BORON CARBIDE PARTICLES AND NEUTRON CAPTURE THERAPY AGENT COMPRISING SAME

Nº publicación: WO2026005041A1 02/01/2026

Solicitante:

RADIONANO THERAPEUTICS INC [JP]
\uFF32\uFF41\uFF44\uFF49\uFF4F\uFF2E\uFF41\uFF4E\uFF4F\u3000\uFF34\uFF48\uFF45\uFF52\uFF41\uFF50\uFF45\uFF55\uFF54\uFF49\uFF43\uFF53\u682A\u5F0F\u4F1A\u793E